Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea
· Delayed Price · Currency is KRW
24,750
+100 (0.41%)
Aug 14, 2025, 3:30 PM KST
Onconic Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 29,425 | 14,838 | 21,056 | 95 | 60 |
| Revenue Growth (YoY) | 442.96% | -29.53% | 22064.25% | 58.33% | - |
| Cost of Revenue | 4.27 | 3.78 | 2.37 | 14,933 | 8,402 |
| Gross Profit | 29,421 | 14,835 | 21,054 | -14,838 | -8,342 |
| Selling, General & Admin | 17,914 | 8,087 | 2,463 | - | - |
| Research & Development | 9,192 | 10,929 | 15,761 | - | - |
| Other Operating Expenses | 134.43 | 164.15 | 138.3 | - | - |
| Operating Expenses | 27,714 | 19,632 | 18,823 | - | - |
| Operating Income | 1,707 | -4,798 | 2,231 | -14,838 | -8,342 |
| Interest Expense | -15.68 | -664.16 | -1,776 | -1,078 | -6,831 |
| Interest & Investment Income | 1,204 | 942.63 | 863.01 | 1,431 | 18.85 |
| Currency Exchange Gain (Loss) | -577.55 | 2,020 | -79.65 | - | - |
| Other Non Operating Income (Expenses) | 0.52 | -7,442 | -576.09 | 52.86 | 5.74 |
| EBT Excluding Unusual Items | 2,319 | -9,942 | 662.51 | -14,432 | -15,149 |
| Gain (Loss) on Sale of Assets | - | - | -0.7 | - | - |
| Pretax Income | 2,319 | -9,942 | 661.81 | -14,432 | -15,149 |
| Income Tax Expense | -2,253 | -1,849 | -1,021 | - | - |
| Net Income | 4,572 | -8,093 | 1,682 | -14,432 | -15,149 |
| Net Income to Common | 4,572 | -8,093 | 1,682 | -14,432 | -15,149 |
| Shares Outstanding (Basic) | - | 8 | 1 | 1 | 1 |
| Shares Outstanding (Diluted) | - | 8 | 1 | 1 | 1 |
| Shares Change (YoY) | - | 1314.60% | -0.00% | 0.94% | - |
| EPS (Basic) | - | -989.81 | 2911.00 | -24969.04 | -26456.01 |
| EPS (Diluted) | - | -989.81 | 2911.00 | -24969.04 | -26456.01 |
| Free Cash Flow | -4,239 | -7,982 | 2,983 | -17,536 | -8,861 |
| Free Cash Flow Per Share | - | -976.30 | 5160.40 | -30339.54 | -15475.92 |
| Gross Margin | 99.98% | 99.98% | 99.99% | - | - |
| Operating Margin | 5.80% | -32.33% | 10.60% | -15618.48% | -13903.24% |
| Profit Margin | 15.54% | -54.54% | 7.99% | -15191.48% | -25247.72% |
| Free Cash Flow Margin | -14.41% | -53.79% | 14.16% | -18458.96% | -14769.11% |
| EBITDA | 2,181 | -4,345 | 2,691 | -14,770 | -8,292 |
| EBITDA Margin | 7.41% | -29.28% | 12.78% | - | - |
| D&A For EBITDA | 473.54 | 452.67 | 460.13 | 67.43 | 49.65 |
| EBIT | 1,707 | -4,798 | 2,231 | -14,838 | -8,342 |
| EBIT Margin | 5.80% | -32.33% | 10.60% | - | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.